Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.
Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.
复制标题
DOI：
10.1517/14656566.2012.642865
复制
发表时间：
2012-01
影响因子：
3.2
通讯作者：
Murphy RL
中科院分区：
文献类型：
--
作者：
Akanbi MO;Scarsi KK;Taiwo B;Murphy RL
目前推荐将两种核苷/核苷酸逆转录酶抑制剂（N（t）RTIs）和另一类抗逆转录病毒药物的第三种药物联合用于初始抗逆转录病毒治疗。一般而言，N（t）RTI在后续治疗方案中仍具有相关性。目前有六种核苷类逆转录酶抑制剂和一种核苷酸类逆转录酶抑制剂药物实体可用，以及几种在固定剂量组合中包含两种或更多种N（t）RTI的制剂。这些实体具有不同的药理学和临床特性。因此，在构建治疗方案时，应考虑毒性、药丸负荷、给药频率、潜在的药物相互作用、预先存在的抗逆转录病毒药物耐药性和合并症。这种方法对于优化病毒学疗效和临床结局至关重要。在这篇文章中，我们回顾了N（t）RTI组合用于治疗HIV感染的成人。每个N（t）RTI的药理学特性，并影响治疗指南的临床试验进行了讨论。尽管人们对无N（t）RTI联合治疗产生了兴趣，但N（t）RTI很可能将继续主导全球HIV治疗和预防领域。仅有少数N（t）RTI替代方案存在的临床领域包括HIV/HBV合并感染和HIV-2的治疗。需要与当前N（t）RTI相比具有增强的安全性和抗性特征的新型N（t）RTI。
The combination of two nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) and a third agent from another antiretroviral class is currently recommended for initial antiretroviral therapy. In general, N(t)RTIs remain relevant in subsequent regimens. There are currently six nucleoside reverse transcriptase inhibitors and one nucleotide reverse transcriptase inhibitor drug entities available, and several formulations that include two or more N(t)RTIs in a fixed dose combination. These entities have heterogeneous pharmacological and clinical properties. Accordingly, toxicity, pill burden, dosing frequency, potential drug-drug interaction, pre-existing antiretroviral drug resistance, and co-morbid conditions should be considered when constructing a regimen. This approach is critical in order to optimize virologic efficacy and clinical outcomes. In this article, we review N(t)RTI combinations used in the treatment of HIV-infected adults. The pharmacological properties of each N(t)RTI, and the clinical trials which have influenced treatment guidelines are discussed. It is likely that N(t)RTIs will continue to dominate the global landscape of HIV treatment and prevention, despite emerging interest in N(t)RTI-free combination therapy. Clinical domains where only few alternatives to N(t)RTIs exist include treatment of HIV/HBV co-infection and HIV-2. There is a need for novel N(t)RTIs with enhanced safety and resistance profiles compared to current N(t)RTIs.
登录
查看更多内容
影响因子：
3.8
作者：
Arribas, Jose R.;Horban, Andrzej;Moecklinghoff, Christiane
通讯作者：
Moecklinghoff, Christiane
DOI：
10.1097/qai.0b013e31815acab8
发表时间：
2008-01-01
影响因子：
3.6
作者：
Arribas, Jose R.;Pozniak, Anton L.;Cheng, Andrew K.
通讯作者：
Cheng, Andrew K.
影响因子：
4.9
作者：
Chappuy, H;Tréluyer, JM;Mandelbrot, L
通讯作者：
Mandelbrot, L
影响因子：
3.8
作者：
Best, BM;Mirochnick, M;Connor, JD
通讯作者：
Connor, JD
影响因子：
168.9
作者：
Brinkman, K;Smeitink, JA;Reiss, P
通讯作者：
Reiss, P